Trial Profile
Effect of Sodium-Glucose Cotransporter-2 inhibitor in patients with type 2 daibetes mellitus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2016
Price :
$35
*
At a glance
- Drugs Ipragliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 02 Nov 2016 Status changed from recruiting to completed.
- 26 Oct 2016 UMIN record has not specified the primary drug of focus for this study. But as per the results, this trial is focusing on SGLT2 inhibitor ipragliflozin. So I have retrived this discarded bundle of UMIN record and integrated results .
- 26 Oct 2016 New trial record